FDA to Review OTC Nasal Spray to Treat Opioid Overdose

Published on January 10, 2023

The FDA has announced that it will be examining an over-the-counter nasal spray manufactured by Emergent Biosolutions Inc. This nasal spray is designed to treat suspected opioid overdoses and is intended for use by the public without a prescription. By evaluating the safety and effectiveness of this product, the FDA aims to provide individuals with a potentially life-saving tool in the fight against opioid overdose. The meeting of the FDA advisory panel, scheduled for February 15th, will play a crucial role in determining whether this nasal spray can become available as an OTC treatment option. As a society, we must explore innovative ways to address the opioid crisis, and this nasal spray has the potential to empower individuals to take immediate action in emergency situations. Understanding the impact and implications of making this medication widely accessible will help inform future strategies in combating the opioid epidemic. To stay informed and learn more about this important development in overdose prevention, I encourage you to explore the full article.

The U.S. health regulator said on Tuesday its advisory panel will meet on Feb. 15 to review Emergent Biosolutions Inc’s over-the-counter (OTC) nasal spray to treat suspected opioid overdoses. Emergent is seeking the Food and Drug Administration’s (FDA) approval for the…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>